Addition of Maintenance Therapy Did Not Meet Primary Endpoint in Lung Cancer Trial

The addition of pemetrexed to bevacizumab maintenance therapy after induction therapy for chemo-naive patients with advanced lung cancer did not meet the primary endpoint in a phase III trial.

Source: CancerNetwork - June 5, 2019 Category: Cancer & Oncology Authors: Jim Kling Source Type: news